BioMarin 3-Year Clinical Data From Ongoing Phase 1/2 Study Of Valoctocogene Roxaparvovec Gene Therapy For Severe Hemophilia A Shows 'Substantial Reduction In Excess Of 92% In Mean Bleed Rate Requiring Factor VIII Infusions'
Benzinga Newsdesk